skip to primary navigationskip to content
 

16th International Conference on Progress in Vaccination Against Cancer (PIVAC-16)

Progress in Vaccination Against Cancer (PIVAC) aims to bring together translational and clinical oncologists and immunologists dealing with active vaccination against cancer for three days of presentations on the most recent advances in the field. The meeting provides an up-to-date overview of many aspects of tumour immunology. Thanks to its friendly atmosphere and the limited number of participants, PIVAC cultivates lively and fruitful discussions, promotes interactions between participants, speakers and companies attending the conference and encourages the emergence of new partnerships.
When Sep 12, 2016 09:00 AM to
Sep 14, 2016 05:00 PM
Where WINCHESTER, UK
Add event to calendar vCal
iCal

Background

The exploitation of the immune system to fight tumours has huge potential, but it still represents a challenge to be overcome. New information has been recently gathered on: the role of the tumour microenvironment as a major factor in determining the immunotherapy outcome; the exploitation of comparative oncology to predict immunotherapy effectiveness; and the potentialities of various vaccination strategies. Moreover, initial positive clinical results are becoming apparent. These new acquisitions will be the focus of PIVAC-16.

Who should attend?

PIVAC is dedicated to scientists working on active immunization against cancer, both in prevention and therapy, at the pre-clinical and/or clinical level. PIVAC is also an ideal environment to stimulate the interest of students and young researchers who approach this field of research.

Topics to be covered in the conference include:

  • Nucleic acid vaccines
  • Plant derived vaccines
  • Viral targeting of cancer
  • Phosphopetide targeting
  • Immunological adjuvancy through PI3K inhibition and chemotherapy
  • Immunostimulatory antibodies
  • Role of B-cells in solid cancers

We look forward to welcoming you to historic Winchester for this exciting conference!

 

More information about this event…

The new Capella building- CITIID

See the home of CITIID being built in this fantastic time-lapse video. From basement to water tight in 17 months. The Capella building will be finished in 2019.

Fibroblast

‘Fibroblast’ has been developed from a conversation between Harold Offeh and Dr Alice Denton, a scientist based at the Babraham Institute and a member of the Cambridge Immunology Network. Offeh was particularly interested in the character and roles played by particular cells in the immune system, as well as the immune system’s role as a primary source of protection and care. The film takes as a starting point microscopic images of broblast cells, an area of research for Dr Denton.

FCEs provide interdisciplinary training programmes for students, fellows and continuing education physicians through FOCIS assisted opportunities

Read more